Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Clinical Trial ID NCT02447003

Rank	Title	Journal	Year	PubWeight™‹?›
1	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.	J Clin Oncol	2016	1.26
2	Clinical relevance of host immunity in breast cancer: from TILs to the clinic.	Nat Rev Clin Oncol	2015	1.22
3	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.	Nat Rev Clin Oncol	2016	1.18
4	Triple-negative breast cancer: treatment challenges and solutions.	Breast Cancer (Dove Med Press)	2016	0.95
5	A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer.	Breast Cancer (Auckl)	2016	0.79
6	Emerging therapeutic targets in metastatic progression: A focus on breast cancer.	Pharmacol Ther	2016	0.79
7	Future perspectives in cancer immunotherapy.	Ann Transl Med	2016	0.77
8	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.	Ther Adv Med Oncol	2016	0.77
9	Concepts and targets in triple-negative breast cancer: recent results and clinical implications.	Ther Adv Med Oncol	2016	0.76